You are here : Home > News Archive > CARBOGEN AMCIS AG Appoints Ville...
CARBOGEN AMCIS AG Appoints Villemagne as VP Commercial

Industry leader Pascal Villemagne to lead global sales

4 October 2011

BUBENDORF, Switzerland (October 4, 2011) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced today the appointment of Pascal Villemagne as vice president commercial. In his new role, Villemagne will lead the company’s overall sales and marketing operations. He will report directly to Mark Griffiths, chief executive officer, and will serve on the company’s executive management team.

 

“CARBOGEN AMCIS provides a continuum of services, from bench to commercial-scale manufacturing. Pascal Villemagne’s commercialization and strategic development experience in the contract research and manufacturing arena will be an important asset to our organization,” says Mark Griffiths, CEO of CARBOGEN AMCIS. “I am very happy to welcome Pascal to CARBOGEN AMCIS’ management team.”

 

Pascal Villemagne brings 15 years of experience in the life science industry, amassed while serving in a variety of commercial leadership roles. Most recently, Villemagne served as vice president, contract manufacturing, at Farmhispania, an API contract manufacturing company based in Spain. Previous roles include sales and business development manager at Inabata and at Cambrex, as well as buyer of raw materials at Sanofi-Aventis.

 

"I am thrilled to join the leadership team of a leading provider of drug development and commercialization services such as CARBOGEN AMCIS,” said Villemagne. “I look forward to expanding the company’s regional sales and marketing strategies and to helping clients make critical decisions in drug development and commercialization more efficiently."

 

Villemagne earned a master of chemistry degree from the University of Lyon, France, and an advanced degree in purchasing from the Saint-Etienne School of Management in Lyon, France.

 

###

 

CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development, allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd., Ahmedabad, India.

 

 

Dishman Group (www.dishmangroup.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and commercial API manufacturing services. Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.

News
21 July 2017
CARBOGEN AMCIS Sites at Bubendorf, Aarau and Neuland in Switzerland Successfully Pass Swissmedic Inspection

11 August 2016
Dishman Celebrates a Decade of Success Since Acquisition of CARBOGEN AMCIS

14 July 2016
CARBOGEN AMCIS Sites at Aarau and Neuland in Switzerland Successfully Pass FDA Inspection


Events
World ADC San Diego

CPhI WW